DJIA 18,024.06 183.54 1.03%
NASDAQ 5,005.39 63.97 1.29%
S&P 500 2,108.29 22.78 1.09%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)



company name or ticker

AbbVie Clearance Sale Going On Now

Gilead Proves Golden: The Importance Of Its Beat-And-Raise Quarter

The Zacks Analyst Blog Highlights: Amgen, Celladon, Kite Pharma, Pharmacyclics and Vertex Pharmaceut

The Zacks Analyst Blog Highlights: Amgen, Celladon, Kite Pharma, Pharmacyclics and Vertex Pharmaceuticals - Press Releases

Celgene to Buy Quanticel, Boost Pipeline Development - Analyst Blog

AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board

AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog

Humira Propels AbbVie Inc. to a Solid First Quarter

AbbVie beats expectations on the strength of Humira, with help from new hep C drug Viekira Pak.

Notable ETF Inflow Detected - FBT, ICPT, PCYC, CLDX

Gilead Sciences Vs. AbbVie: Which Is A Better Buy?

Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog

See More Articles...